Advertisement
Singapore markets closed

  • Straits Times Index

    3,410.81
    -29.07 (-0.85%)
     

  • Nikkei

    40,912.37
    -1.28 (-0.00%)
     

  • Hang Seng

    17,799.61
    -228.67 (-1.27%)
     

  • FTSE 100

    8,203.93
    -37.33 (-0.45%)
     

  • Bitcoin USD

    57,453.28
    +858.13 (+1.52%)
     

  • CMC Crypto 200

    1,191.35
    -17.34 (-1.43%)
     

  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     

  • Dow

    39,375.87
    +67.87 (+0.17%)
     

  • Nasdaq

    18,352.76
    +164.46 (+0.90%)
     

  • Gold

    2,399.80
    +30.40 (+1.28%)
     

  • Crude Oil

    83.44
    -0.44 (-0.52%)
     

  • 10-Yr Bond

    4.2720
    -0.0830 (-1.91%)
     

  • FTSE Bursa Malaysia

    1,611.02
    -5.73 (-0.35%)
     

  • Jakarta Composite Index

    7,253.37
    +32.48 (+0.45%)
     

  • PSE Index

    6,492.75
    -14.74 (-0.23%)
     

European regulator endorses high-dose version of Bayer eye drug Eylea

Reuters
·1-min read

FRANKFURT, Nov 10 (Reuters) - Bayer said on Friday that the European Medicines Agency recommended approval of a higher dose version of eye drug Eylea for treatment of a leading cause of blindness among the elderly, stepping up competition with Roche.

The European Commission, which has the final word on drug approvals in the EU, typically follows the recommendations issued by the EMA.

A go-ahead would mean that Eylea, an injection in the eye also known as aflibercept and jointly developed with Regeneron , can be given in doses of 8 milligrams instead of the usual 2 milligrams, allowing for longer intervals between injections. (Reporting by Ludwig Burger; editing by Matthias Williams)